Skip to main content

Percutaneous Tibial Nerve Stimulation

Percutaneous tibial nerve stimulation (PTNS) is a minimally invasive neuromodulation therapy primarily used for the treatment of overactive bladder (OAB) and urgency urinary incontinence, with emerging but more controversial evidence for fecal incontinence and chronic pelvic pain. It is a guideline-recommended therapy endorsed by the AUA/SUFU and EAU as a treatment option for OAB refractory to behavioral and pharmacologic therapies.[1][2][3]

This page is the canonical tibial-nerve stimulation target for the OAB database, including PTNS, TTNS, and implantable tibial systems. It is intentionally separate from Sacral Neuromodulation because the procedures, maintenance burden, and device counseling are different. PTNS sits alongside Intradetrusor OnabotulinumtoxinA and SNM in the third-line tier of the AUA/SUFU 2024 OAB ladder.

Mechanism of Action​

PTNS delivers retrograde electrical stimulation to the sacral nerve plexus (S2–S4) via the posterior tibial nerve, a mixed sensory-motor nerve that shares common nerve roots with the pelvic floor and bladder.[4] The exact mechanism remains incompletely understood, but research suggests stimulation modulates central and peripheral neural pathways involved in bladder control. Animal studies indicate that recruitment of unmyelinated C-fibers mediates the bladder-inhibitory effects, and co-activation of the adjacent saphenous nerve may also contribute.[5][6][7]

Technique and Protocol​

A 34-gauge stainless steel needle is inserted percutaneously approximately 5 cm cephalad to the medial malleolus and slightly posterior to the tibia, at approximately a 60° angle. A surface electrode is placed on the ipsilateral calcaneus. The needle is connected to a low-voltage stimulator delivering a fixed-frequency electrical signal.[4][8]

Standard stimulation parameters:

  • Frequency: 20 Hz
  • Pulse width: 200 μs
  • Current: 0.5–9 mA (titrated to patient tolerance — typically to elicit toe flexion or a tingling sensation in the sole of the foot)
  • Session duration: 30 minutes
  • Treatment course: Once weekly for 12 weeks (induction phase), followed by periodic maintenance sessions[8][9][10]

The effect is relatively short-lived, and ongoing maintenance treatments (typically monthly or as needed) are required to sustain benefit.[1][9]

Clinical Indications​

  • Overactive bladder (OAB) — the primary and best-supported indication, including urgency, frequency, nocturia, and urgency urinary incontinence
  • Neurogenic detrusor overactivity — evidence in multiple sclerosis and Parkinson's disease[9]
  • Fecal incontinence — studied but with mixed results (see below)
  • Chronic pelvic pain / interstitial cystitis — limited evidence with lower efficacy compared to OAB[11][12]

Efficacy for Overactive Bladder​

The SUmiT trial (n=220), a pivotal multicenter double-blind sham-controlled RCT, demonstrated that 54.5% of PTNS patients reported moderate or marked improvement vs. 20.9% with sham (p < 0.001).[13]

A meta-analysis of 28 studies (n=2,461) reported a pooled success rate of 68% (95% CI 59–78%), with significant reductions in voiding frequency (−2.48/day), nocturia (−1.57/day), urgency episodes (−2.20/day), and incontinence episodes (−1.37/day).[14]

Comparison with Other Therapies​

ComparisonKey findingsEvidence
PTNS vs. ShamSuperior for all OAB parameters; 54.5% vs. 20.9% improvement (SUmiT)[13]
PTNS vs. AntimuscarinicsComparable efficacy for frequency, nocturia, urgency, and UUI; PTNS has significantly fewer adverse events and lower discontinuation rates[2][3][15]
PTNS vs. Sacral NeuromodulationSNM may produce greater reductions in incontinence episodes; PTNS has fewer side effects but shorter-lived effects[16]
PTNS vs. OnabotulinumtoxinABoth effective; botulinum toxin associated with higher UTI and urinary retention rates[16]
PTNS vs. Pelvic Floor Muscle TrainingPTNS performs better than conservative therapy alone[2]

The EAU classifies PTNS as a first-line treatment option alongside antimuscarinics and beta-3 agonists.[3] The AUA/SUFU 2024 guidelines recommend tibial nerve stimulation, sacral neuromodulation, and intradetrusor botulinum toxin as options for patients with inadequate response to behavioral or pharmacologic therapy (Moderate Recommendation, Grade A evidence), and also allow offering minimally invasive therapies without requiring prior conservative treatment trials.[2]

Efficacy for Fecal Incontinence​

Evidence for PTNS in fecal incontinence is mixed. A prospective cohort study (n=150) showed sustained improvement in FI scores up to 42 months with maintenance sessions.[17] However, the CONFIDeNT trial (n=227), a large double-blind RCT, found no significant difference between PTNS and sham (38% vs. 31% achieved ≥50% reduction in FI episodes, p=0.396).[8] Similarly, the NOTABLE trial (n=166 women) found that PTNS did not differ from sham stimulation for FI severity.[18] A smaller RCT did show a modest advantage for PTNS over sham in reducing median FI episodes.[19] Overall, the evidence does not strongly support PTNS for fecal incontinence based on sham-controlled data.[20]

Safety and Adverse Effects​

PTNS has an excellent safety profile. The most common adverse event is mild pain at the needle insertion site, with low incidence.[8][14] No serious device-related adverse events have been reported in major trials.[8][13] Notably, PTNS does not increase post-void residual volume (unlike antimuscarinics or botulinum toxin) and does not involve a metallic implant, preserving MRI compatibility.[9]

Contraindications​

Based on clinical trial exclusion criteria and manufacturer guidance:[4]

  • Pregnancy or planned pregnancy
  • Presence of an implanted electro-medical device (pacemaker, defibrillator, InterStim)
  • Skin conditions at the treatment site
  • Pelvic radiation history
  • Current lower urinary tract malignancy
  • Peripheral neuropathy affecting the lower extremity (relative)

Limitations and Practical Considerations​

  • Short-lived effect requiring ongoing maintenance sessions, which can be burdensome[1][9]
  • Patient compliance is limited by the need for weekly in-office visits during induction[1]
  • Insurance coverage may be limited to a finite number of lifetime sessions[1]
  • These limitations have driven the development of implantable tibial nerve stimulation devices, at least two of which have received FDA marketing authorization, offering at-home stimulation with the same mechanism of action[1]
  • A poor PTNS response does not necessarily predict SNM failure; the targets and stimulation patterns differ

Transcutaneous Alternative (TTNS)​

Transcutaneous tibial nerve stimulation (TTNS) uses surface electrodes rather than a needle and can be performed at home. Meta-analyses suggest comparable efficacy to PTNS for reducing voiding frequency, though evidence is more limited.[21] TTNS is particularly useful for neurological patients for whom repeated office visits are difficult.[9]

See Also​

Videos​

Percutaneous Tibial Nerve Stimulation (PTNS) for Overactive Bladder
HCA Florida Healthcare (2022)

References​

1. Lee UJ, MacDiarmid S, Matthews CA, Gillespie E, Peters KM. "Tibial Nerve Stimulation for Urge Urinary Incontinence and Overactive Bladder: Narrative Review of Randomized Controlled Trials and Applicability to Implantable Devices." Adv Ther. 2024;41(7):2635-2654. doi:10.1007/s12325-024-02864-3

2. Cameron AP, Chung DE, Dielubanza EJ, et al. "The AUA/SUFU Guideline on the Diagnosis and Treatment of Idiopathic Overactive Bladder." J Urol. 2024;212(1):11-20. doi:10.1097/JU.0000000000003985

3. Farag F, Sakalis VI, Arteaga SM, et al. "What Are the Short-Term Benefits and Potential Harms of Therapeutic Modalities for the Management of Overactive Bladder Syndrome in Women? A Review of Evidence Under the Auspices of the EAU Female Non-Neurogenic LUTS Guidelines Panel." Eur Urol. 2023;84(3):302-312. doi:10.1016/j.eururo.2023.05.014

4. Stewart F, Gameiro LF, El Dib R, et al. "Electrical Stimulation With Non-Implanted Electrodes for Overactive Bladder in Adults." Cochrane Database Syst Rev. 2016;12:CD010098. doi:10.1002/14651858.CD010098.pub4

5. Li X, Li X, Liao L. "Mechanism of Action of Tibial Nerve Stimulation in the Treatment of Lower Urinary Tract Dysfunction." Neuromodulation. 2024;27(2):256-266. doi:10.1016/j.neurom.2023.03.017

6. Paquette JP, Yoo PB. "Recruitment of Unmyelinated C-Fibers Mediates the Bladder-Inhibitory Effects of Tibial Nerve Stimulation in a Continuous-Fill Anesthetized Rat Model." Am J Physiol Renal Physiol. 2019;317(1):F163-F171. doi:10.1152/ajprenal.00502.2018

7. Elder CW, Yoo PB. "A Finite Element Modeling Study of Peripheral Nerve Recruitment by Percutaneous Tibial Nerve Stimulation in the Human Lower Leg." Med Eng Phys. 2018;53:32-38. doi:10.1016/j.medengphy.2018.01.004

8. Knowles CH, Horrocks EJ, Bremner SA, et al. "Percutaneous Tibial Nerve Stimulation Versus Sham Electrical Stimulation for the Treatment of Faecal Incontinence in Adults (CONFIDeNT): A Double-Blind, Multicentre, Pragmatic, Parallel-Group, Randomised Controlled Trial." Lancet. 2015;386(10004):1640-8. doi:10.1016/S0140-6736(15)60314-2

9. Panicker JN, Fowler CJ, Kessler TM. "Lower Urinary Tract Dysfunction in the Neurological Patient: Clinical Assessment and Management." Lancet Neurol. 2015;14(7):720-32. doi:10.1016/S1474-4422(15)00070-8

10. Zomkowski K, Kammers I, Back BBH, et al. "The Effectiveness of Different Electrical Nerve Stimulation Protocols for Treating Adults With Non-Neurogenic Overactive Bladder: A Systematic Review and Meta-Analysis." Int Urogynecol J. 2022;33(5):1045-1058. doi:10.1007/s00192-022-05088-7

11. Tutolo M, Ammirati E, Heesakkers J, et al. "Efficacy and Safety of Sacral and Percutaneous Tibial Neuromodulation in Non-Neurogenic Lower Urinary Tract Dysfunction and Chronic Pelvic Pain: A Systematic Review of the Literature." Eur Urol. 2018;73(3):406-418. doi:10.1016/j.eururo.2017.11.002

12. Biemans JM, van Balken MR. "Efficacy and Effectiveness of Percutaneous Tibial Nerve Stimulation in the Treatment of Pelvic Organ Disorders: A Systematic Review." Neuromodulation. 2013;16(1):25-33. doi:10.1111/j.1525-1403.2012.00504.x

13. Peters KM, Carrico DJ, Perez-Marrero RA, et al. "Randomized Trial of Percutaneous Tibial Nerve Stimulation Versus Sham Efficacy in the Treatment of Overactive Bladder Syndrome: Results From the SUmiT Trial." J Urol. 2010;183(4):1438-43. doi:10.1016/j.juro.2009.12.036

14. Wang M, Jian Z, Ma Y, et al. "Percutaneous Tibial Nerve Stimulation for Overactive Bladder Syndrome: A Systematic Review and Meta-Analysis." Int Urogynecol J. 2020;31(12):2457-2471. doi:10.1007/s00192-020-04429-8

15. Xia L, Yan H, Sun Y, et al. "Pooled Analysis of the Efficacy and Safety of Tibial Nerve Stimulation Versus Antimuscarinic Agents in the Management of Overactive Bladder Syndrome." Medicine. 2021;100(45):e27745. doi:10.1097/MD.0000000000027745

16. Lo CW, Wu MY, Yang SS, Jaw FS, Chang SJ. "Comparing the Efficacy of OnabotulinumtoxinA, Sacral Neuromodulation, and Peripheral Tibial Nerve Stimulation as Third Line Treatment for the Management of Overactive Bladder Symptoms in Adults: Systematic Review and Network Meta-Analysis." Toxins. 2020;12(2):E128. doi:10.3390/toxins12020128

17. Hotouras A, Murphy J, Walsh U, et al. "Outcome of Percutaneous Tibial Nerve Stimulation (PTNS) for Fecal Incontinence: A Prospective Cohort Study." Ann Surg. 2014;259(5):939-43. doi:10.1097/SLA.0b013e3182a6266c

18. Zyczynski HM, Richter HE, Sung VW, et al. "Percutaneous Tibial Nerve Stimulation vs Sham Stimulation for Fecal Incontinence in Women: NeurOmodulaTion for Accidental Bowel Leakage Randomized Clinical Trial." Am J Gastroenterol. 2022;117(4):654-667. doi:10.14309/ajg.0000000000001605

19. van der Wilt AA, Giuliani G, Kubis C, et al. "Randomized Clinical Trial of Percutaneous Tibial Nerve Stimulation Versus Sham Electrical Stimulation in Patients With Faecal Incontinence." Br J Surg. 2017;104(9):1167-1176. doi:10.1002/bjs.10590

20. Tahmasbi F, Mosaddeghi-Heris R, Soleimanzadeh F, et al. "Effects of Posterior Tibial Nerve Stimulation on Fecal Incontinence: An Umbrella Review." Neuromodulation. 2024;27(2):229-242. doi:10.1016/j.neurom.2023.06.004

21. Ghavidel-Sardsahra A, Ghojazadeh M, Rahnama'I MS, et al. "Efficacy of Percutaneous and Transcutaneous Posterior Tibial Nerve Stimulation on Idiopathic Overactive Bladder and Interstitial Cystitis/Painful Bladder Syndrome: A Systematic Review and Meta-Analysis." Neurourol Urodyn. 2022;41(2):539-551. doi:10.1002/nau.24864